reVision Therapeutics Attends Stargardt’s Connected Community Zoom

October 4, 2023

On September 9th, reVision participated in the Stargardt’s Connected Community Zoom session. Dr. Paul Fehlner, co-founder and CEO of reVision, provided an overview of our lead program, REV-0100, for Stargardt disease, a rare pediatric retinal disease. REV-0100 has the potential to expand to dry age-related macular degeneration (AMD). During the session, he discussed various aspects of REV-0100, including its mechanism of action, in vivo efficacy in Stargardt mouse models, systemic safety, competitive advantage, and development timeline. Additionally, he introduced the Scientific Advisory Board and reVision’s team to the Stargardt’s Connected Community.

The reVision team was thrilled to have the opportunity to engage with Stargardt’s Connected and answer questions from their board and members. At reVision, hearing from patients motivates the team and provides us with a sense of connection to those whose lives we have the ability to impact most.

You can watch the presentation on the Stargardt’s Connected YouTube channel.